The diagnostic efficacy of serum galectin-3 and other markers in papillary thyroid carcinoma.

ABSTRACT:

Background

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, representing approximately 85-90% of cases. Galectin-3 (GAL-3) is a well-established histologic marker of thyroid cancer that is not expressed by normal thyroid cells. Our study aims to explore the potential utility of serum GAL-3 in differentiating PTC from benign thyroid tumors.

Methods

According to the postoperative pathology results, patients were divided into a benign thyroid tumor group (95 cases) and a PTC group (165 cases). Serum GAL-3 was detected by chemiluminescence immunoassay. Additionally, other markers, including human epidermal growth factor receptor 2 (HER2), Ki-67, cytokeratin 19 (CK19), thyroid peroxidase (TPO), and CD56, were detected by enzyme-linked immunosorbent ass

SUBMITTER: Zhang X 

PROVIDER: S-EPMC12685786 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature